Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of HepaRegeniX.

    Client Virtual Booth

    HEPAREGENIX

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    HepaRegeniX
    Germany Flag
    Country
    Country
    Germany
    Address
    Address
    Alfred-Mendler-Weg 25/1, 89075 Ulm
    Telephone
    Telephone
    +49 (0)7071 6396731
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.heparegenix.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    HepaRegeniX Publishes Data for Its First-In-Class MKK4 inhibitor HRX-215 for the treatment of Acute and Chronic Liver Diseases in Cell

    Details:

    HRX-0215 is a small molecule inhibitor of MKK4, a key regulator of liver regeneration. It is being evaluated for the treatment of hepatic steatosis, liver damage & nonalcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma.


    Lead Product(s): HRX-215

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: HRX-215

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 14, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Boehringer, Novo-backed German biotech banks €11M in liver regeneration push

    Details:

    The proceeds will be used to advance the first MKK4 inhibitor for treatment of acute and chronic liver diseases to the clinics later in 2020.


    Lead Product(s): Undisclosed

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Undisclosed

    Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

    Deal Size: $12.2 million Upfront Cash: Undisclosed

    Deal Type: Series B Financing January 21, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search